Lenka Radova

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9698705/publications.pdf

Version: 2024-02-01

89 papers

2,603 citations

186265 28 h-index 206112 48 g-index

90 all docs 90 docs citations

90 times ranked 5244 citing authors

#	Article	IF	CITATIONS
1	Role of miR-653 and miR-29c in downregulation of CYP1A2 expression in hepatocellular carcinoma. Pharmacological Reports, 2022, 74, 148-158.	3.3	О
2	l-lactate kinetics after abdominal aortic surgery and intestinal ischemia – An observational cohort study. International Journal of Surgery, 2022, 98, 106220.	2.7	O
3	A GP1BA Variant in a Czech Family with Monoallelic Bernard-Soulier Syndrome. International Journal of Molecular Sciences, 2022, 23, 885.	4.1	1
4	STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma. Leukemia, 2021, 35, 1500-1505.	7.2	29
5	Epithelial to mesenchymal transition and microRNA expression are associated with spindle and apocrine cell morphology in triple-negative breast cancer. Scientific Reports, 2021, 11, 5145.	3.3	16
6	Low-burden <i>TP53</i> mutations in CLL: clinical impact and clonal evolution within the context of different treatment options. Blood, 2021, 138, 2670-2685.	1.4	29
7	Complex Interplay of Genes Underlies Invasiveness in Fibrosarcoma Progression Model. Journal of Clinical Medicine, 2021, 10, 2297.	2.4	O
8	Small RNA Sequencing Identifies PIWI-Interacting RNAs Deregulated in Glioblastomaâ€"piR-9491 and piR-12488 Reduce Tumor Cell Colonies In Vitro. Frontiers in Oncology, 2021, 11, 707017.	2.8	6
9	Nucleotides in both donor and acceptor splice sites are responsible for choice in NAGNAG tandem splice sites. Cellular and Molecular Life Sciences, 2021, 78, 6979-6993.	5.4	3
10	LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients. Biomedicines, 2021, 9, 1637.	3.2	3
11	Functional analysis of germline ETV6 W380R mutation causing inherited thrombocytopenia and secondary acute lymphoblastic leukemia or essential thrombocythemia. Platelets, 2020, 32, 1-4.	2.3	2
12	Hepatocellular carcinoma: Gene expression profiling and regulation of xenobiotic-metabolizing cytochromes P450. Biochemical Pharmacology, 2020, 177, 113912.	4.4	24
13	Profiling of biological and environmental risk factors in immunogenetic subgroups of chronic lymphocytic leukemia - Czech national study. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2020, 164, 425-434.	0.6	0
14	MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells. Leukemia, 2019, 33, 403-414.	7.2	46
15	Cerebrospinal Fluid MicroRNA Signatures as Diagnostic Biomarkers in Brain Tumors. Cancers, 2019, 11, 1546.	3.7	45
16	Novel genetic variant of HPS1 gene in Hermansky-Pudlak syndrome with fulminant progression of pulmonary fibrosis: a case report. BMC Pulmonary Medicine, 2019, 19, 178.	2.0	7
17	ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients. Leukemia and Lymphoma, 2019, 60, 1420-1428.	1.3	20
18	MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients. Cancer Genomics and Proteomics, 2019, 16, 353-359.	2.0	17

#	Article	IF	CITATIONS
19	Bending of DNA duplexes with mutation motifs. DNA Research, 2019, 26, 341-352.	3.4	5
20	High-throughput analysis revealed mutations' diverging effects on <i>SMN1</i> exon 7 splicing. RNA Biology, 2019, 16, 1364-1376.	3.1	8
21	MicroRNA-15b-5p Predicts Locoregional Relapse in Head and Neck Carcinoma Patients Treated With Intensity-modulated Radiotherapy. Cancer Genomics and Proteomics, 2019, 16, 139-146.	2.0	21
22	A novel germline mutation of the SFTPA1 gene in familial interstitial pneumonia. Human Genome Variation, 2019, 6, 12.	0.7	15
23	CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase. Leukemia, 2019, 33, 518-558.	7.2	15
24	Tumor expression of miR-34a-3p is an independent predictor of recurrence in non–muscle-invasive bladder cancer and promising additional factor to improve predictive value of EORTC nomogram. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 184.e1-184.e7.	1.6	11
25	Activation-induced deaminase and its splice variants associate with trisomy 12 in chronic lymphocytic leukemia. Annals of Hematology, 2019, 98, 423-435.	1.8	2
26	Identification of microRNA signatures in umbilical cord blood associated with maternal characteristics. PeerJ, 2019, 7, e6981.	2.0	5
27	Bioinformatic pipelines for whole transcriptome sequencing data exploitation in leukemia patients with complex structural variants. PeerJ, 2019, 7, e7071.	2.0	1
28	Identification of microRNAs differentially expressed in glioblastoma stem-like cells and their association with patient survival. Scientific Reports, 2018, 8, 2836.	3.3	37
29	Genomeâ€wide identification of urinary cellâ€free micro <scp>RNA</scp> s for nonâ€invasive detection of bladder cancer. Journal of Cellular and Molecular Medicine, 2018, 22, 2033-2038.	3.6	36
30	Transcription factor YY1 can control AlDâ€mediated mutagenesis in mice. European Journal of Immunology, 2018, 48, 273-282.	2.9	5
31	Expression of COBLL1 encoding novel ROR1 binding partner is robust predictor of survival in chronic lymphocytic leukemia. Haematologica, 2018, 103, 313-324.	3.5	16
32	A novel germline mutation in <i>GP1BA</i> gene N-terminal domain in monoallelic Bernard-Soulier syndrome. Platelets, 2018, 29, 827-833.	2.3	8
33	Circulating PIWI-Interacting RNAs piR-5937 and piR-28876 Are Promising Diagnostic Biomarkers of Colon Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1019-1028.	2.5	77
34	Circulating exosomal long noncoding RNA PRINSâ€"First findings in monoclonal gammopathies. Hematological Oncology, 2018, 36, 786-791.	1.7	39
35	C-terminal RUNX1 mutation in familial platelet disorder with predisposition to myeloid malignancies. International Journal of Hematology, 2018, 108, 652-657.	1.6	8
36	Deregulated expression of long nonâ€coding <scp>RNA UCA</scp> 1 in multiple myeloma. European Journal of Haematology, 2017, 99, 223-233.	2.2	40

#	Article	IF	CITATIONS
37	The Root Growth-Regulating Brevicompanine Natural Products Modulate the Plant Circadian Clock. ACS Chemical Biology, 2017, 12, 1466-1471.	3.4	9
38	Micro <scp>RNA</scp> and mesial temporal lobe epilepsy with hippocampal sclerosis: Whole mi <scp>RN</scp> ome profiling of human hippocampus. Epilepsia, 2017, 58, 1782-1793.	5.1	41
39	MiR-215-5p is a tumor suppressor in colorectal cancer targeting EGFR ligand epiregulin and its transcriptional inducer HOXB9. Oncogenesis, 2017, 6, 399.	4.9	74
40	Single cell analysis revealed a coexistence of <i><scp>NOTCH</scp>1</i> and <i><scp>TP</scp>53</i> mutations within the same cancer cells in chronic lymphocytic leukaemia patients. British Journal of Haematology, 2017, 178, 979-982.	2.5	5
41	DNA mutation motifs in the genes associated with inherited diseases. PLoS ONE, 2017, 12, e0182377.	2.5	20
42	A small molecule drug promoting miRNA processing induces alternative splicing of MdmX transcript and rescues p53 activity in human cancer cells overexpressing MdmX protein. PLoS ONE, 2017, 12, e0185801.	2.5	18
43	Global MicroRNA Expression Profiling Identifies Unique MicroRNA Pattern of Radioresistant Glioblastoma Cells. Anticancer Research, 2017, 37, 1099-1104.	1.1	13
44	Comprehensive group therapy of obesity and its impact on selected anthropometric and postural parameters. Central European Journal of Public Health, 2017, 25, 326-331.	1.1	3
45	Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy. OncoTargets and Therapy, 2016, Volume 9, 4695-4703.	2.0	12
46	ATM mutations in major stereotyped subsets of chronic lymphocytic leukemia: enrichment in subset #2 is associated with markedly short telomeres. Haematologica, 2016, 101, e369-e373.	3.5	16
47	Clinical and pathogenic features of <i>ETV6</i> -related thrombocytopenia with predisposition to acute lymphoblastic leukemia. Haematologica, 2016, 101, 1333-1342.	3.5	92
48	Epithelial-mesenchymal transition-associated microRNA/mRNA signature is linked to metastasis and prognosis in clear-cell renal cell carcinoma. Scientific Reports, 2016, 6, 31852.	3.3	37
49	Centrosome associated genes pattern for risk sub-stratification in multiple myeloma. Journal of Translational Medicine, 2016, 14, 150.	4.4	18
50	Serum-based microRNA signatures in early diagnosis and prognosis prediction of colon cancer. Carcinogenesis, 2016, 37, 941-950.	2.8	141
51	Decreased <i><scp>WNT</scp>3</i> expression in chronic lymphocytic leukaemia is a hallmark of disease progression and identifies patients with worse prognosis in the subgroup with mutated <i><scp>IGHV</scp></i> . British Journal of Haematology, 2016, 175, 851-859.	2.5	13
52	Nonâ€invasive prognostic protein biomarker signatures associated with colorectal cancer. EMBO Molecular Medicine, 2015, 7, 1153-1165.	6.9	49
53	MicroRNAs in urine are not biomarkers of multiple myeloma. Journal of Negative Results in BioMedicine, 2015, 14, 16.	1.4	4
54	Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma. PLoS ONE, 2015, 10, e0137294.	2.5	16

#	Article	IF	Citations
55	miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib. BioMed Research International, 2015, 2015, 1-5.	1.9	41
56	MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab. Oncotarget, 2015, 6, 38695-38704.	1.8	67
57	Evaluation of HER2 Gene Status in Breast Cancer Samples with Indeterminate Fluorescence in Situ Hybridization by Quantitative Real-Time PCR. Journal of Molecular Diagnostics, 2015, 17, 446-455.	2.8	20
58	BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy. Tumor Biology, 2015, 36, 4243-4252.	1.8	29
59	Dynamic changes in microRNA expression profiles reflect progression of Barrett's esophagus to esophageal adenocarcinoma. Carcinogenesis, 2015, 36, 521-527.	2.8	44
60	Combination of serum microRNAâ€320a and microRNAâ€320b as a marker for <scp>W</scp> aldenström macroglobulinemia. American Journal of Hematology, 2015, 90, E51-2.	4.1	8
61	Lycopene improves the distorted ratio between AA/DHA in the seminal plasma of infertile males and increases the likelihood of successful pregnancy. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2015, 159, 077-082.	0.6	13
62	Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica, 2014, 99, 511-518.	3.5	94
63	Which health professionals are most at risk for cardiovascular disease? Or do not be a manager. International Journal of Occupational Medicine and Environmental Health, 2014, 27, 71-7.	1.3	5
64	Risk Score based on microRNA expression signature is independent prognostic classifier of glioblastoma patients. Carcinogenesis, 2014, 35, 2756-2762.	2.8	30
65	Hepcidin levels in Diamond-Blackfan anemia reflect erythropoietic activity and transfusion dependency. Haematologica, 2014, 99, e118-e121.	3.5	13
66	Predictive parameters for internal mammary node drainage in patients with early breast cancer. Tumori, 2014, 100, 254-8.	1.1	8
67	Combination of prednisolone and low dosed dexamethasone exhibits greater in vitro antileukemic activity than equiactive dose of prednisolone and overcomes prednisolone drug resistance in acute childhood lymphoblastic leukemia. Biomedical Papers of the Medical Faculty of the University Palacky&:#x0301:. Olomouc. Czechoslovakia. 2014. 158. 422-427.	0.6	6
68	MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma. Tumor Biology, 2013, 34, 481-491.	1.8	70
69	Expression of multidrug resistance protein 1 and multidrug resistance-associated protein 1 in peripheral blood lymphocytes amongst children and young adults. Central-European Journal of Immunology, 2013, 4, 518-529.	1.2	0
70	Correlation between BRCA1 expression and clinicopathological factors including brain metastases in patients with non-small-cell lung cancer. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2013, 157, 227-232.	0.6	3
71	Copy number changes in triple-negative breast cancer: New molecular targets Journal of Clinical Oncology, 2013, 31, 1063-1063.	1.6	0
72	Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. International Journal of Oncology, 2012, 41, 1204-1212.	3.3	20

#	Article	IF	Citations
73	Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. Journal of Translational Medicine, 2012, 10, 55.	4.4	228
74	Common polymorphisms in GSTM1, GSTT1, GSTP1, GSTA1 and susceptibility to colorectal cancer in the Central European population. European Journal of Medical Research, 2012, 17, 17.	2.2	39
75	Identification and functional screening of micro <scp>RNA</scp> s highly deregulated in colorectal cancer. Journal of Cellular and Molecular Medicine, 2012, 16, 2655-2666.	3.6	127
76	MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Radiation Oncology, 2012, 7, 195.	2.7	111
77	Cancer Cell Response to Anthracyclines Effects: Mysteries of the Hidden Proteins Associated with These Drugs. International Journal of Molecular Sciences, 2012, 13, 15536-15564.	4.1	17
78	Evaluation of laparoscopic resection of colorectal carcinoma from the viewpoint of molecular biology. Wideochirurgia I Inne Techniki Maloinwazyjne, 2012, 1, 19-26.	0.7	2
79	Evaluation of SNPs in miR-196-a2, miR-27a and miR-146a as risk factors of colorectal cancer. World Journal of Gastroenterology, 2012, 18, 2827.	3.3	102
80	Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients. Genes Chromosomes and Cancer, 2012, 51, 707-716.	2.8	97
81	BCL2 protein in prediction of relapse in triple-negative breast cancer (TNBC) treated with adjuvant anthracycline-based chemotherapy Journal of Clinical Oncology, 2012, 30, 1087-1087.	1.6	4
82	Analysis of the prognostic impact of nestin expression in non-small cell lung cancer. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2012, 156, 135-142.	0.6	13
83	High lapatinib plasma levels in breast cancer patients: risk or benefit?. Tumori, 2012, 98, 162-5.	1.1	2
84	Changes of microRNAs-192, 196a and 203 correlate with Barrett's esophagus diagnosis and its progression compared to normal healthy individuals. Diagnostic Pathology, 2011, 6, 114.	2.0	42
85	The immunohistochemical expression of BNIP3 protein in nonâ€smallâ€cell lung cancer: a tissue microarray study. Apmis, 2010, 118, 565-570.	2.0	4
86	IDENTIFICATION OF CD133+/NESTIN+ PUTATIVE CANCER STEM CELLS IN NON-SMALL CELL LUNG CANCER. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2010, 154, 321-326.	0.6	46
87	The measurement of reactive oxygen species in human neat semen and in suspended spermatozoa: a comparison. Reproductive Biology and Endocrinology, 2009, 7, 118.	3.3	20
88	Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study. Journal of Cancer Research and Clinical Oncology, 2008, 134, 1037-1042.	2.5	89
89	PROGNOSTIC VALUE OF hMLH1 AND hMSH2 IMMUNOHISTOCHEMICAL EXPRESSION IN NON-SMALL CELL LUNG CANCER. A TISSUE MICROARRAY STUDY. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2006, 150, 255-259.	0.6	9